EFTR Tiesioginiai signalai | Didinkite pelną su Getagraph.com

PARDAVIMAS 109128 min ago

@ $11.19

Išleistas: 13 vas. 2024 @ 17:58

Grąža: -83.11%

Live Chart Being Loaded With Signals

Commentary (26 bal. 2024 @ 23:00):

eFFECTOR Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of selective translation regulator inhibitors for the treatment of cancer...

Stats
Šios dienos apimtis	161 694
Vidutinė apimtis	382 382
Rinkos kapitalizacija	6.97M
EPS	$-3.42 ( 2024-03-27 )
Kita pelno data	( $-2.17 ) 2024-05-14
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.120
ATR14	$0.0120 (0.63%)

Insider Trading

Date	Person	Action	Amount	type
2024-02-19	Loewy Caroline M	Buy	2 000	Stock Option (Right to Buy)
2024-02-19	Bhatt Elizabeth	Buy	2 000	Stock Option (Right to Buy)
2024-02-19	Ehrlich Christopher B	Buy	2 000	Stock Option (Right to Buy)
2024-02-19	Klencke Barbara	Buy	2 000	Stock Option (Right to Buy)
2024-02-19	Harrington-smith Kristen	Buy	2 000	Stock Option (Right to Buy)

INSIDER POWER
45.06
Last 95 transactions
Buy: 5 541 401 \| Sell: 1 016 887

Tūris Koreliacija

Ilgas: -0.09 (neutral)

Trumpas: -0.54 (weak negative)

Signal:(48.371) Neutral

eFFECTOR Therapeutics, Koreliacija

10 Labiausiai teigiamai susiję koreliacijos
APOP	0.91
FLGT	0.875
PIII	0.875
PRSR	0.871
MAGS	0.871
SOFIW	0.867
CMLF	0.867
LPTX	0.864
AGCUU	0.863
WKSP	0.863

10 Labiausiai neigiamai susiję koreliacijos
ULTA	-0.855
IEP	-0.845
TNDM	-0.833
IART	-0.83
ASO	-0.829
CDAK	-0.828
IQ	-0.827
PAYS	-0.827
SBNYP	-0.817
PHCF	-0.815

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

eFFECTOR Therapeutics, Koreliacija - Valiuta/Žaliavos

-0.04
( neutral )

0.15
( neutral )

0.00
( neutral )

0.09
( neutral )

0.61
( weak )

-0.16
( neutral )

eFFECTOR Therapeutics, Finansinės ataskaitos

Annual	2023
Pajamos:	$0
Bruto pelnas:	$-111 000 (0.00 %)
EPS:	$-16.37

FY	2023
Pajamos:	$0
Bruto pelnas:	$-111 000 (0.00 %)
EPS:	$-16.37

FY	2022
Pajamos:	$3.55M
Bruto pelnas:	$3.50M (98.51 %)
EPS:	$-7.85

FY	2021
Pajamos:	$0.00
Bruto pelnas:	$0.00 (0.00 %)
EPS:	$1.050

Financial Reports:

No articles found.

eFFECTOR Therapeutics,

eFFECTOR Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of selective translation regulator inhibitors for the treatment of cancer. Its lead product candidate is Tomivosertib, an oral small-molecule inhibitor of MNK that is in phase 2b clinical trial for the treatment of patients with metastatic non-small cell lung cancer. The company is also developing Zotatifin, a small molecule designed to inhibit eukaryotic initiation factor 4A (eIF4E), which is in phase 2clinical trial to treat patients with solid tumors. It has a collaboration agreement with Pfizer Inc. to develop inhibitors of eIF4E. eFFECTOR Therapeutics, Inc. was founded in 2012 and is headquartered in Solana Beach, California.